For instance, B7-H3 ICI therapy could be used to treat PD-L1-expressing tumors that do not respond adequately to PD-L1 ICI therapy, as combination therapy with two ICIs has already been used to treat NSCLC with other B7 family ligands. This evidence concerns the gene CD80 and non-small cell lung carcinoma.